Target Validation Information
Target ID T84486
Target Name Oxytocin receptor
Target Type
Successful
Drug Potency against Target PF-3274167 Drug Info Ki = 9.5 nM [530975]
[Lys8(Alexa 546) ]PVA Drug Info Ki = 1.95 nM [529036]
[Mpa1, D-Tic2, Aib7]OT Drug Info IC50 = 8500 nM [528693]
[Mpa1, L-Tic7]OT Drug Info IC50 = 103 nM [528693]
[Mpa1, D-Tyr(Et)2, Aib7, D-Tic9]OT Drug Info IC50 = 55 nM [528693]
L-371257 Drug Info Ki = 19 nM [530975]
L-372662 Drug Info Ki = 14 nM [530975]
D[Leu4,Dap8]VP Drug Info Ki = 134 nM [528674]
D[Orn4,Orn8]VP Drug Info Ki = 37 nM [528674]
D[Orn4]AVP Drug Info Ki = 997 nM [528674]
D[Cha4]AVP Drug Info Ki = 1430 nM [528674]
D[Leu4,Dab8]VP Drug Info Ki = 41 nM [528674]
D[Leu4,Lys8]VP Drug Info Ki = 64 nM [528674]
D[Thr4,Orn8(5/6C-Flu)]VT Drug Info Ki = 0.4 nM [526347]
DesGly-NH2,d(CH2)5[D-Tyr2,Thr4,Orn8(5/6C-Flu)]VT Drug Info Ki = 126 nM [526347]
[HO1][Orn8(5/6C-Flu)]VT Drug Info Ki = 0.18 nM [526347]
Carbetocin Drug Info Affinity = 7.24+/-0.29 nM [553278]
[Mpa1, D-Tyr(Et)2, D-Tic7, Aib9]OT Drug Info IC50 = 80 nM [528693]
1'-tosylspiro[indene-1,4'-piperidine] Drug Info Ki = 1600 nM [530975]
[D-Tic7]OT Drug Info IC50 = 730 nM [528693]
D[Cha4,Dap8]VP Drug Info Ki = 1200 nM [528674]
[Mpa1, D-Tyr(Et)2, L-Tic7]OT Drug Info IC50 = 176 nM [528693]
[Mpa1, D-Tyr(Et)2, D-Tic7, D-Tic9]OT Drug Info IC50 = 25 nM [528693]
D[Arg4,Orn8]VP Drug Info Ki = 130 nM [528674]
D[Arg4,Dab8]VP Drug Info Ki = 195 nM [528674]
D[Leu4]AVP Drug Info Ki = 481 nM [528674]
D[Arg4,Lys8]VP Drug Info Ki = 125 nM [528674]
[Mpa1, D-Tyr(Et)2, D-Tic7]OT Drug Info IC50 = 51 nM [528693]
[L-Tic7]OT Drug Info IC50 = 130 nM [528693]
D[Lys8(5/6-Flu)]VT Drug Info Ki = 0.29 nM [526347]
[Pip7]OT Drug Info IC50 = 7 nM [528693]
[Mpa1, D-Tyr(Et)2, Gly(But)7]OT Drug Info IC50 = 1002 nM [528693]
[Mpa1, D-Tyr(Et)2, Gly(But)3, Gly(But)7]OT Drug Info IC50 = 7850 nM [528693]
[Gly(But)7]OT Drug Info IC50 = 1380 nM [528693]
[Aib7]OT Drug Info IC50 = 75 nM [528693]
[Mpa1, D-Tic7]OT Drug Info IC50 = 380 nM [528693]
[Mpa1, D-Tyr(Et)2, Aib7]OT Drug Info IC50 = 485 nM [528693]
[Mpa1, D-Tyr(Et)2, Pip7]OT Drug Info IC50 = 40 nM [528693]
[HO1][Thr4,Lys8(5/6C-Flu)]VT Drug Info Ki = 0.32 nM [526347]
SR-149415 Drug Info Ki = 19 nM [530420]
D[Cha4,Orn8]VP Drug Info Ki = 550 nM [528674]
D[Arg4]AVP Drug Info Ki = 3550 nM [528674]
D[Leu4,Orn8]VP Drug Info Ki = 55 nM [528674]
ARGENINE VASOPRESSIN Drug Info Ki = 1.17 nM [528674]
D[Orn4,Lys8]VP Drug Info Ki = 22 nM [528674]
D[Cha4,Lys8]VP Drug Info Ki = 590 nM [528674]
[HO1][Lys8(5/6C-Flu)]VT Drug Info Ki = 0.34 nM [526347]
D(CH2)5[Tyr(Me)2,Thr4,Orn8(5/6C-Flu),Tyr-NH29]VT Drug Info Ki = 6.24 nM [526347]
D[Orn8(5/6C-Flu)]VT Drug Info Ki = 0.25 nM [526347]
ATOSIBAN Drug Info IC50 = 12 nM [527874]
Retosiban Drug Info Ki = 0.65 nM [529164]
[Lys8(Alexa 488) ]PVA Drug Info Ki = 1.04 nM [529036]
D[Cha4,Dab8]VP Drug Info Ki = 430 nM [528674]
D[Val4]AVP Drug Info Ki = 826 nM [528674]
[HO1][Thr4,Orn8(5/6C-Flu)]VT Drug Info Ki = 0.17 nM [526347]
D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT Drug Info Ki = 0.21 nM [526347]
D[Thr4,Lys8(5/6C-Flu)]VT Drug Info Ki = 1.8 nM [526347]
References
Ref 530975J Med Chem. 2010 Sep 23;53(18):6525-38.Oral oxytocin antagonists.
Ref 529036J Med Chem. 2007 Oct 4;50(20):4976-85. Epub 2007 Sep 12.Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 530975J Med Chem. 2010 Sep 23;53(18):6525-38.Oral oxytocin antagonists.
Ref 530975J Med Chem. 2010 Sep 23;53(18):6525-38.Oral oxytocin antagonists.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 526347J Med Chem. 2002 Jun 6;45(12):2579-88.Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Ref 526347J Med Chem. 2002 Jun 6;45(12):2579-88.Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Ref 526347J Med Chem. 2002 Jun 6;45(12):2579-88.Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Ref 553278[International therapeutic trial comparing the value of radical mastectomy(Halsted) and extended mastectomy (Halsted plus internal mammary node dissection in the treatment of breast cancer. 5-year results].
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 530975J Med Chem. 2010 Sep 23;53(18):6525-38.Oral oxytocin antagonists.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 526347J Med Chem. 2002 Jun 6;45(12):2579-88.Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 528693Eur J Med Chem. 2007 Jun;42(6):799-806. Epub 2007 Jan 10.Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Ref 526347J Med Chem. 2002 Jun 6;45(12):2579-88.Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Ref 530420Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22. Epub 2009 Sep 17.Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 526347J Med Chem. 2002 Jun 6;45(12):2579-88.Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Ref 526347J Med Chem. 2002 Jun 6;45(12):2579-88.Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Ref 526347J Med Chem. 2002 Jun 6;45(12):2579-88.Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Ref 527874Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9. Epub 2005 Nov 15.Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.
Ref 529164Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. Epub 2007 Nov 6.The discovery of GSK221149A: a potent and selective oxytocin antagonist.
Ref 529036J Med Chem. 2007 Oct 4;50(20):4976-85. Epub 2007 Sep 12.Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 528674J Med Chem. 2007 Feb 22;50(4):835-47.Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Ref 526347J Med Chem. 2002 Jun 6;45(12):2579-88.Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Ref 526347J Med Chem. 2002 Jun 6;45(12):2579-88.Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
Ref 526347J Med Chem. 2002 Jun 6;45(12):2579-88.Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.